Related Experiment Video
Updated: May 1, 2026
08:37
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
16.5K
Increased suppressor cell activity in inflammatory bowel disease.
Gut
|December 1, 1981
Summary
Indomethacin boosts prostaglandin-producing suppressor cells in inflammatory bowel disease (IBD) patients, while sulphasalazine and 5-ASA reduce cell response. These drugs have opposing effects in IBD immunopathology.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD) involves complex immune dysregulation.
- Peripheral blood mononuclear cells (PBMC) play a role in immune responses.
- Understanding drug effects on immune cells is crucial for IBD treatment.
Purpose of the Study:
- To investigate the in vitro effects of indomethacin, hydrocortisone, sulphasalazine, and its metabolites (sulphapyridine and 5-ASA) on PBMC from IBD patients and controls.
- To elucidate the immunomodulatory mechanisms of these drugs in the context of IBD.
- To determine potential interactions between indomethacin and sulphasalazine on PBMC function.
Main Methods:
- In vitro study analyzing PBMC responses to mitogens (PHA-P) after drug incubation.
- Comparison of drug effects between 49 IBD patients and 34 healthy controls.
- Assessment of drug effects independent of HLA type, disease activity, or current therapy.
Main Results:
- Indomethacin significantly increased PBMC response to PHA-P, suggesting enhanced prostaglandin-producing suppressor cell activity (P < 0.01).
- Sulphasalazine and 5-ASA reduced PBMC response (P < 0.05), with a greater effect in IBD patients.
- Indomethacin counteracted the suppressive effect of sulphasalazine on PBMC (P < 0.001).
Conclusions:
- Increased prostaglandin-producing suppressor cell activity may contribute to IBD immunopathology.
- Sulphasalazine's therapeutic effect likely does not involve direct modulation of this suppressor cell system.
- Indomethacin and sulphasalazine exhibit opposing in vitro immunomodulatory mechanisms relevant to IBD treatment considerations.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.6K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
34
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34
01:25Inflammatory Bowel Disease III: Crohn's Disease
35
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
35